You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 708 A phase 1/2 study of rinatabart sesutecan (PRO1184), a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
708 A phase 1/2 study of rinatabart sesutecan (PRO1184), a novel folate receptor alpha-directed antibody-drug conjugate, in patients with locally advanced and/or metastatic solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023532084
Dec 2023266055
Jan 2024273039
Feb 2024310044
Mar 2024404055
Apr 202414340192
May 2024860090
Jun 2024853098
Jul 202412100100
Aug 202412810133
Sep 20241481094
Oct 20241556090
Nov 20241362099
Dec 202412560112
Jan 202515240121
Feb 2025654093
Mar 20258098
Apr 20250074
May 20250051
Jun 20250041
Total1526401763